Haemonetics (HAE) Stock Price
Haemonetics Price
Haemonetics (HAE) Stock | ISIN US4050241003 | WKN 881782. The current Haemonetics stock price is 77.58 USD (2026). Revenue is 1.34 B USD. Net income is 230.61 M USD. The P/E ratio is 17.07. Market capitalization is 3.61 B USD. Haemonetics operates in the Health sector.
Over the last 19 years Haemonetics grew revenue by 6.4% annually, reaching 1.36 B USD. Earnings per share have grown at 5.3% per year over the last 19 years. For Haemonetics, the net margin of 12.3% is up versus 9.1% a few years ago.
Haemonetics stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Haemonetics over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Haemonetics stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Haemonetics's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Haemonetics Price |
|---|
Haemonetics Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Haemonetics Income Statement, Balance Sheet, Cash Flow Statement
| REVENUE (B USD) |
|---|
| REVENUE GROWTH (%) |
| GROSS MARGIN (%) |
| GROSS INCOME (M USD) |
| NET INCOME (M USD) |
| NET INCOME GROWTH (%) |
| SHARES (M) |
| DOCUMENTS |
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|
| 0.87 | 0.99 | 1.17 | 1.31 | 1.36 | 1.34 | 1.41 | 1.5 |
| -11.94 | 14.14 | 17.62 | 12.07 | 3.9 | -1.62 | 5.46 | 6.52 |
| 46.78 | 52.87 | 53.25 | 54.09 | 56.1 | 57.03 | 54.08 | 50.77 |
| 407 | 525 | 622 | 708 | 763 | 763 | 763 | 763 |
| 79 | 43 | 115 | 117 | 167 | 230 | 255 | 286 |
| 3.95 | -45.57 | 167.44 | 1.74 | 42.74 | 37.72 | 10.87 | 12.16 |
| 51.3 | 51.4 | 51.4 | 51.4 | 50.73 | 50.73 | 50.73 | 50.73 |
| – | – | – | – | – | – | – | – |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Haemonetics generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Haemonetics retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Haemonetics's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Haemonetics has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Haemonetics's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Haemonetics stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Haemonetics Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Haemonetics business model & stock analysis
Haemonetics SWOT Analysis
Strengths
Haemonetics Corp has several strengths that contribute to its position in the market:
- Strong brand reputation and recognition in the healthcare industry.
- Wide range of innovative and high-quality products and services.
- Solid financial performance and stability.
- Strong research and development capabilities.
- Effective distribution network and global presence.
Weaknesses
Despite its strengths, Haemonetics Corp also faces certain weaknesses:
- Dependence on a limited number of major customers.
- Relatively high production costs and potential pricing pressures.
- Dependency on regulatory approvals for new product launches.
- Limited diversification across healthcare sectors and geographies.
Opportunities
There are several opportunities that Haemonetics Corp can capitalize on:
- Growing global healthcare market and increasing demand for blood management solutions.
- Expansion into emerging markets with high growth potential.
- Innovation and development of new products and technologies.
- Strategic partnerships and collaborations to enhance market reach.
- Acquisition or integration of complementary businesses to increase market share.
Threats
Haemonetics Corp must also address certain threats that may impact its business:
- Intense competition from existing and new players in the market.
- Changing regulatory environment and potential compliance challenges.
- Fluctuating exchange rates and economic uncertainties.
- Rapid technological advancements and the need to keep up with industry trends.
- Supply chain disruptions and challenges in sourcing raw materials.
Haemonetics Segments
Haemonetics Revenue by Segment (1/4)
3 Years
5 Years
10 Years
Max
Details
Haemonetics Revenue by Segment (2/4)
Max
Details
Haemonetics Revenue by Segment (3/4)
3 Years
5 Years
10 Years
Max
Details
Haemonetics Revenue by Segment (4/4)
Max
Details
Haemonetics Revenue by Region
3 Years
5 Years
10 Years
Max
Details
Haemonetics Eulerpool Fair Value
Haemonetics historical P/E ratio, EBIT multiple, and P/S ratio
Haemonetics annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Haemonetics shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Haemonetics Earnings Estimates
Haemonetics Earnings Estimates
| Date | EPS estimate | Revenue Estimate | Quarterly report |
|---|---|---|---|
| 5/7/2026 | 1.28USD | 340.23 MUSD | 2026 Q4 |
| 2/5/2026 | 1.26USD | 334.93 MUSD | 2026 Q3 |
| 2/4/2026 | 1.26USD | 334.95 MUSD | 2026 Q3 |
| 5/9/2024 | 0.93USD | 321.41 MUSD | 2024 Q4 |
| 2/5/2024 | 0.95USD | 324.97 MUSD | 2024 Q3 |
| 8/8/2023 | 0.64USD | 271.95 MUSD | 2024 Q1 |
| 5/8/2023 | 0.71USD | 287.39 MUSD | 2023 Q4 |
| 2/6/2023 | 0.81USD | 300.58 MUSD | 2023 Q3 |
| 11/7/2022 | 0.68USD | 273.26 MUSD | 2023 Q2 |
| 8/10/2022 | 0.52USD | 252.74 MUSD | 2023 Q1 |
EESG©
Eulerpool ESG Scorecard© for the Haemonetics stock
EEnvironment
20
Environment
SSocial
20
Social
GGovernance (Corporate Governance)
4
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
Haemonetics shareholder structure
| % | Name |
|---|---|
11.9847% | |
10.63514% | |
9.20476% | |
4.61865% | |
4.05419% | |
3.56289% | |
3.43204% | |
2.73522% | |
2.67834% | |
2.45114% |
Haemonetics Executives and Management Board
Mr. Christopher Simon
(61)President, Chief Executive Officer, Director · since 2016
Mr. James D'Arecca
(54)Executive Vice President, Chief Financial Officer
Ms. Michelle Basil
(53)Executive Vice President, General Counsel
Mr. Josep Llorens
(62)Executive Vice President - Global Manufacturing and Supply Chain
Mr. Roy Galvin
(56)Executive Vice President, Chief Commercial Officer
Haemonetics Supply Chain
Frequently asked questions about Haemonetics
The business model of Haemonetics Corp focuses on providing innovative and comprehensive solutions for blood and plasma collection, as well as transfusion medicine. This global healthcare company specializes in the development and manufacturing of devices and software that aid in blood management, including blood processing systems, information technology solutions, and donor management software. Haemonetics Corp aims to improve patient outcomes and enhance operational efficiency in blood and plasma centers, hospitals, and other healthcare settings worldwide through its integrated offerings.
Haemonetics stock
Haemonetics Peer Group
Haemonetics Ticker
Haemonetics FIGI
All fundamentals and in-depth analysis of Haemonetics
Our stock analysis for Haemonetics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Haemonetics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.